Filter the drugs by their COVID-19 status ,phase of research and how they help

COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. Browse the database of potential drugs for COVID-19 treatment compiled by the AIM tool.
Substance COVID-19 status Phase of research  How it helps Latest publication
MI-30
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/18/2021
(Recombinant) IL-2
Potential treatment - clinical evidence Experimental Other treatment Jan/18/2021
1-{4-[(Methoxyacetyl)amino]phenyl}-N-(3-methoxypropyl)cyclohexanecarboxamide
Potential treatment - theoretical effect Experimental Antiviral
Menstrual blood-derived stem cells
Potential treatment - clinical evidence Experimental Other treatment Mar/06/2021
ZyCoV-D
Emergency use authorization Experimental Vaccine Mar/26/2020
WNbFc 36
Potential treatment - pre-clinical evidence Experimental Antiviral Apr/23/2021
mAB 4-8
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/12/2021
2-(Morpholin-4-yl)-2-oxoethyl 6-(4-methoxyphenyl)-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylate
Potential treatment - theoretical effect Experimental Antiviral Dec/17/2020
N-(3-(Furan-2-yl)-1-(4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)-1H-pyrazol-5-yl)-3-methylbenzamide
Potential treatment - theoretical effect Experimental Antiviral Dec/17/2020
GS‐441524
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/19/2021
WNbFc 15
Potential treatment - pre-clinical evidence Experimental Antiviral Apr/23/2021
mAB 2-17
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/12/2021
CoV-X2
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/25/2021
WNbFc 7
Potential treatment - pre-clinical evidence Experimental Antiviral Apr/23/2021
mAB 4-18
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/12/2021
ACE2‐TMPRSS2‐EVs
Potential treatment - pre-clinical evidence Experimental Antiviral Dec/28/2020
TPNT1
Potential treatment - pre-clinical evidence Experimental Antiviral Apr/22/2021
S-FL-opt/S1 recombinant protein
Potential treatment - pre-clinical evidence Experimental Vaccine Feb/08/2021
P2B-2F6
Potential treatment - pre-clinical evidence Experimental Antiviral May/26/2020
WNbFc 2
Potential treatment - pre-clinical evidence Experimental Antiviral Apr/23/2021